Skip to main content

Sartorius and ProMetic to Supply, Develop Plasma Protein-Separation Technology

NEW YORK, April 3 (GenomeWeb News) - Sartorius and ProMetic BioTherapeutics, a subsidiary of ProMetic Life Sciences, will jointly supply and develop technology for separate proteins from blood plasma, the companies said today.

 

ProMetic, based in Montreal, Canada, has been licensing its plasma protein -purification technology to the blood industry. Under the agreement, Sartorius of Göttingen, Germany, will supply licensees of ProMetic's technology with filtration equipment and consumables as a "preferred supplier and technology provider," according to the companies.

 

In addition, the two partners will co-develop ligand-membrane composites for the isolation of proteins from blood plasma and other sources, based on ProMetic's Mimetic Ligand technology and Sartorius' membrane chromatography technology, Sartobind.

 

The companies did not disclose financial terms of the agreement.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.